Status:

COMPLETED

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)

Lead Sponsor:

Swedish Orphan Biovitrum

Collaborating Sponsors:

Kantar Health

Cerner Enviza (former Kantar Health)

Conditions:

Hemophilia A

Hemophilia B

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported f...

Detailed Description

The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported f...

Eligibility Criteria

Inclusion

  • A patient must fulfil the following criteria in order to be included in the study:
  • Age ≥18 years.
  • Diagnosis of haemophilia A or B.
  • Capable of completing the study Patient-Reported Outcome (PRO) questionnaires in French.
  • Signed informed consent.

Exclusion

  • The presence of any of the following criteria will exclude a patient from inclusion in the study:
  • Joint replacement within last 6 months.
  • Patients with a non-resolved joint or muscle bleeding event at the enrolment visit or ≤ 7 days prior to the enrolment visit.
  • Patients with comorbid illnesses such as juvenile arthritis, muscular dystrophy, neurologic illness/cognitive impairment, or other illnesses that may independently affect HJHS and Hemo-FAST scores and/or limit the ability of the patient to participate in the study as determined by the investigator.

Key Trial Info

Start Date :

May 5 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 19 2022

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT04731701

Start Date

May 5 2021

End Date

July 19 2022

Last Update

September 19 2024

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Swedish Orphan Biovitrum Clinical site

Paris, Cochin, France

2

Swedish Orphan Biovitrum Clinical site

Paris, Kremlin-Bicêtre, France

3

Swedish Orphan Biovitrum Clinical site

Besançon, France

4

Swedish Orphan Biovitrum Clinical site

Bordeaux, France